Four Decades for Justice
Sharonmoyee Goswami focuses her practice on intellectual property, antitrust and litigation involving complex scientific issues. She has extensive experience representing companies and individuals in all stages of litigation, from pre‑complaint investigation through appeal, and routinely practices before the Patent Trial and Appeal Board (PTAB).
IAM Patent 1000 has recognized Ms. Goswami’s work in the patent litigation area, pointing to her “exceptional command of the law, technical dexterity, intellect and positivity.” The publication has also noted that she is “extremely strategic and detail‑oriented and knows how to position cases to maximise chances of success.”
Ms. Goswami’s notable representations include:
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Ms. Goswami obtained an unprecedented trial win, in which the FTC's Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC's challenge to the merger. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Illumina in antitrust litigation filed by Complete Genomics and related entities in California federal court alleging that Illumina unlawfully asserted certain patents against plaintiffs in an anticompetitive manner. The case settled on grounds favorable to Illumina.
Secured favorable settlements for Truist Bank in patent infringement litigation brought by United Services Automobile Association (“USAA”) in Texas federal court concerning patents that relate to remote check deposits for mobile banking, and in associated IPR proceedings.
Represented Amgen in litigation concerning its introduction of a biosimilar to AbbVie’s biologic drug, Humira®—the world’s largest‑selling drug—in one of the first cases to proceed under the Biologics Price Competition and Innovation Act (BPCIA). Amgen reached a global settlement with AbbVie that enabled Amgen to market the first approved biosimilar to Humira® in the U.S. and Europe.
Won a jury verdict for Amgen in a patent infringement case in Delaware federal court against Sanofi and Regeneron relating to Amgen’s patents covering a class of biologic drugs that treat high cholesterol.
Obtained a jury verdict for DRIT, an investment partnership, in a patent licensing dispute against Glaxo Group over the lupus drug Benlysta®.
Ms. Goswami serves as Chair of the Patents Committee of the New York City Bar Association, as a Vice Chair of the Federal Circuit Bar Association’s PTAB and Trademark Trial and Appeal Board (TTAB) Committee, and has previously served on Law360’s Life Sciences Editorial Advisory Board. She is a member of the Diversity Committee of the PTAB Bar Association and a Director of the South Asian Bar Association of New York.
For her patent litigation work, Ms. Goswami has been repeatedly recognized by IAM Patent 1000 and The Legal 500 US, including as a “Next Generation Partner.” She was named a 2023 "Rising Star" by The New York Law Journal, and Benchmark Litigation has recognized her as a "Future Star" and named her to its “40 & Under List.” Ms. Goswami has also been named to Lawdragon’s “500 Leading Litigators in America” and “500 X – The Next Generation” lists. In 2022, she received LMG Life Sciences’ “US Rising Star – Intellectual Property” award and Euromoney Legal Media Group’s Rising Star Award for “Best in Patent,” and she was named to Patexia Insight’s list of Top IPR Attorneys of 2022.
Ms. Goswami was born in Washington, D.C. She received a B.S.E. in Chemical Engineering from Princeton University in 2009 and obtained certificates (minors) in Engineering Biology and Materials Science. At Princeton, she was awarded the inaugural leadership prize in Materials Science and Engineering. She received a J.D. magna cum laude from New York University School of Law in 2012, where she was a Florence Allen Scholar, a Senior Editor of the Journal of Intellectual Property & Entertainment Law and was elected to the Order of the Coif. At NYU, she was awarded the Walter J. Derenberg Prize in Copyright Law. She also received the Sidney B. Williams, Jr. scholarship from the Foundation for Advancement of Diversity in IP Law.
Ms. Goswami joined Cravath in 2012. She served as a law clerk to Hon. Timothy B. Dyk of the U.S. Court of Appeals for the Federal Circuit in 2013. She rejoined Cravath in 2014 and was elected a partner in 2019. Ms. Goswami serves on the Firm’s Diversity Committee and is a partner liaison to the South Asian Affinity Group/Middle Eastern Affinity Group.
Ms. Goswami’s notable representations include:
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Ms. Goswami obtained an unprecedented trial win, in which the FTC's Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC's challenge to the merger. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Illumina in antitrust litigation filed by Complete Genomics and related entities in California federal court alleging that Illumina unlawfully asserted certain patents against plaintiffs in an anticompetitive manner. The case settled on grounds favorable to Illumina.
Secured favorable settlements for Truist Bank in patent infringement litigation brought by United Services Automobile Association (“USAA”) in Texas federal court concerning patents that relate to remote check deposits for mobile banking, and in associated IPR proceedings.
Represented Amgen in litigation concerning its introduction of a biosimilar to AbbVie’s biologic drug, Humira®—the world’s largest‑selling drug—in one of the first cases to proceed under the Biologics Price Competition and Innovation Act (BPCIA). Amgen reached a global settlement with AbbVie that enabled Amgen to market the first approved biosimilar to Humira® in the U.S. and Europe.
Won a jury verdict for Amgen in a patent infringement case in Delaware federal court against Sanofi and Regeneron relating to Amgen’s patents covering a class of biologic drugs that treat high cholesterol.
Obtained a jury verdict for DRIT, an investment partnership, in a patent licensing dispute against Glaxo Group over the lupus drug Benlysta®.
Ms. Goswami serves as Chair of the Patents Committee of the New York City Bar Association, as a Vice Chair of the Federal Circuit Bar Association’s PTAB and Trademark Trial and Appeal Board (TTAB) Committee, and has previously served on Law360’s Life Sciences Editorial Advisory Board. She is a member of the Diversity Committee of the PTAB Bar Association and a Director of the South Asian Bar Association of New York.
For her patent litigation work, Ms. Goswami has been repeatedly recognized by IAM Patent 1000 and The Legal 500 US, including as a “Next Generation Partner.” She was named a 2023 "Rising Star" by The New York Law Journal, and Benchmark Litigation has recognized her as a "Future Star" and named her to its “40 & Under List.” Ms. Goswami has also been named to Lawdragon’s “500 Leading Litigators in America” and “500 X – The Next Generation” lists. In 2022, she received LMG Life Sciences’ “US Rising Star – Intellectual Property” award and Euromoney Legal Media Group’s Rising Star Award for “Best in Patent,” and she was named to Patexia Insight’s list of Top IPR Attorneys of 2022.
Ms. Goswami was born in Washington, D.C. She received a B.S.E. in Chemical Engineering from Princeton University in 2009 and obtained certificates (minors) in Engineering Biology and Materials Science. At Princeton, she was awarded the inaugural leadership prize in Materials Science and Engineering. She received a J.D. magna cum laude from New York University School of Law in 2012, where she was a Florence Allen Scholar, a Senior Editor of the Journal of Intellectual Property & Entertainment Law and was elected to the Order of the Coif. At NYU, she was awarded the Walter J. Derenberg Prize in Copyright Law. She also received the Sidney B. Williams, Jr. scholarship from the Foundation for Advancement of Diversity in IP Law.
Ms. Goswami joined Cravath in 2012. She served as a law clerk to Hon. Timothy B. Dyk of the U.S. Court of Appeals for the Federal Circuit in 2013. She rejoined Cravath in 2014 and was elected a partner in 2019. Ms. Goswami serves on the Firm’s Diversity Committee and is a partner liaison to the South Asian Affinity Group/Middle Eastern Affinity Group.
Federal Circuit Bar Association, PTAB and TTAB Committee
New York City Bar Association, Patents Committee
PTAB Bar Association, Diversity Committee
South Asian Bar Association of New York
Law360
Benchmark Litigation
Euromoney Legal Media Group
Intellectual Asset Management
Lawdragon
The Legal 500 US
New York Law Journal
Deals & Cases
January 31, 2023
In January, 2023, Cravath client Abiomed Inc. (“Abiomed”) secured a victory before the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”).
Deals & Cases
September 02, 2022
On September 1, 2022, Chief Administrative Law Judge D. Michael Chappell of the Federal Trade Commission (“FTC”) ruled in favor of Cravath client Illumina, rejecting the FTC’s challenge to Illumina’s $8 billion acquisition of GRAIL, which closed in August 2021.
Accolades
October 11, 2023
On October 2, 2023, Cravath partner Sharonmoyee Goswami was featured as a 2023 “Rising Star” by the New York Law Journal. The accompanying profile published by NYLJ highlights Sharon’s representation of clients across all stages of litigation related to complex scientific issues, from pre‑complaint investigation through appeal, and her pro bono work involving issues including asylum, employment discrimination and hate crime litigation. Sharon also shared advice for young lawyers, encouraging them to know their “client’s business backwards and forwards” to become “a go‑to resource for the client as well as for the partners and senior associates on your team,” which can lead to greater leadership opportunities.
Accolades
August 10, 2023
On August 9, 2023, Cravath partner Sharonmoyee Goswami was named a 2023 “Rising Star” by the New York Law Journal. The award recognizes “the New York legal community’s emerging leaders.” Winners will be featured online and honored at an event in October.
Accolades
August 02, 2023
Cravath partners Michael P. Addis, Helam Gebremariam, Sharonmoyee Goswami, Lauren R. Kennedy, David H. Korn, Lauren M. Rosenberg, Brittany L. Sukiennik and Michael J. Zaken were named by Benchmark Litigation to its 2023 “40 & Under List.” The list honors the achievements of the nation’s most accomplished litigators of 40 years old and under who are “leading high‑profile cases and building significant reputations in their respective practices.” The list was compiled through a process involving peer and client review, along with examination of individual cases.
Activities & Publications
February 07, 2023
On January 31, 2023, Cravath partner Sharonmoyee Goswami participated in a program entitled “Patent Law Year in Review 2022,” which was hosted virtually by the Federal Circuit Bar Association, of which Sharon is vice chair of the PTAB and TTAB Committee. Sharon’s session discussed developments in patent law in 2022, including enablement and written description, patent venue, litigation procedures and key decisions issued by the Federal Circuit, and Patent Trial and Appeal Board (“PTAB”) proceedings.
Activities & Publications
December 06, 2022
On December 1, 2022, Cravath partner Sharonmoyee Goswami participated in a webcast entitled “PTAB Ten Years After: Where Are We Now and Where are We Going?” which was hosted by The Federal Circuit Bar Association’s PTAB and TTAB Committee, of which Sharon is vice chair. Sharon moderated the session, which examined the increasing usage of Inter Partes Reviews and Post‑Grant Reviews, recent actions of the U.S. Patent Trial and Appeal Board, and the prospect for post‑grant proceedings in the future.
Sharonmoyee Goswami focuses her practice on intellectual property, antitrust and litigation involving complex scientific issues. She has extensive experience representing companies and individuals in all stages of litigation, from pre‑complaint investigation through appeal, and routinely practices before the Patent Trial and Appeal Board (PTAB).
IAM Patent 1000 has recognized Ms. Goswami’s work in the patent litigation area, pointing to her “exceptional command of the law, technical dexterity, intellect and positivity.” The publication has also noted that she is “extremely strategic and detail‑oriented and knows how to position cases to maximise chances of success.”
Ms. Goswami’s notable representations include:
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Ms. Goswami obtained an unprecedented trial win, in which the FTC's Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC's challenge to the merger. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Illumina in antitrust litigation filed by Complete Genomics and related entities in California federal court alleging that Illumina unlawfully asserted certain patents against plaintiffs in an anticompetitive manner. The case settled on grounds favorable to Illumina.
Secured favorable settlements for Truist Bank in patent infringement litigation brought by United Services Automobile Association (“USAA”) in Texas federal court concerning patents that relate to remote check deposits for mobile banking, and in associated IPR proceedings.
Represented Amgen in litigation concerning its introduction of a biosimilar to AbbVie’s biologic drug, Humira®—the world’s largest‑selling drug—in one of the first cases to proceed under the Biologics Price Competition and Innovation Act (BPCIA). Amgen reached a global settlement with AbbVie that enabled Amgen to market the first approved biosimilar to Humira® in the U.S. and Europe.
Won a jury verdict for Amgen in a patent infringement case in Delaware federal court against Sanofi and Regeneron relating to Amgen’s patents covering a class of biologic drugs that treat high cholesterol.
Obtained a jury verdict for DRIT, an investment partnership, in a patent licensing dispute against Glaxo Group over the lupus drug Benlysta®.
Ms. Goswami serves as Chair of the Patents Committee of the New York City Bar Association, as a Vice Chair of the Federal Circuit Bar Association’s PTAB and Trademark Trial and Appeal Board (TTAB) Committee, and has previously served on Law360’s Life Sciences Editorial Advisory Board. She is a member of the Diversity Committee of the PTAB Bar Association and a Director of the South Asian Bar Association of New York.
For her patent litigation work, Ms. Goswami has been repeatedly recognized by IAM Patent 1000 and The Legal 500 US, including as a “Next Generation Partner.” She was named a 2023 "Rising Star" by The New York Law Journal, and Benchmark Litigation has recognized her as a "Future Star" and named her to its “40 & Under List.” Ms. Goswami has also been named to Lawdragon’s “500 Leading Litigators in America” and “500 X – The Next Generation” lists. In 2022, she received LMG Life Sciences’ “US Rising Star – Intellectual Property” award and Euromoney Legal Media Group’s Rising Star Award for “Best in Patent,” and she was named to Patexia Insight’s list of Top IPR Attorneys of 2022.
Ms. Goswami was born in Washington, D.C. She received a B.S.E. in Chemical Engineering from Princeton University in 2009 and obtained certificates (minors) in Engineering Biology and Materials Science. At Princeton, she was awarded the inaugural leadership prize in Materials Science and Engineering. She received a J.D. magna cum laude from New York University School of Law in 2012, where she was a Florence Allen Scholar, a Senior Editor of the Journal of Intellectual Property & Entertainment Law and was elected to the Order of the Coif. At NYU, she was awarded the Walter J. Derenberg Prize in Copyright Law. She also received the Sidney B. Williams, Jr. scholarship from the Foundation for Advancement of Diversity in IP Law.
Ms. Goswami joined Cravath in 2012. She served as a law clerk to Hon. Timothy B. Dyk of the U.S. Court of Appeals for the Federal Circuit in 2013. She rejoined Cravath in 2014 and was elected a partner in 2019. Ms. Goswami serves on the Firm’s Diversity Committee and is a partner liaison to the South Asian Affinity Group/Middle Eastern Affinity Group.
Ms. Goswami’s notable representations include:
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Ms. Goswami obtained an unprecedented trial win, in which the FTC's Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC's challenge to the merger. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Illumina in antitrust litigation filed by Complete Genomics and related entities in California federal court alleging that Illumina unlawfully asserted certain patents against plaintiffs in an anticompetitive manner. The case settled on grounds favorable to Illumina.
Secured favorable settlements for Truist Bank in patent infringement litigation brought by United Services Automobile Association (“USAA”) in Texas federal court concerning patents that relate to remote check deposits for mobile banking, and in associated IPR proceedings.
Represented Amgen in litigation concerning its introduction of a biosimilar to AbbVie’s biologic drug, Humira®—the world’s largest‑selling drug—in one of the first cases to proceed under the Biologics Price Competition and Innovation Act (BPCIA). Amgen reached a global settlement with AbbVie that enabled Amgen to market the first approved biosimilar to Humira® in the U.S. and Europe.
Won a jury verdict for Amgen in a patent infringement case in Delaware federal court against Sanofi and Regeneron relating to Amgen’s patents covering a class of biologic drugs that treat high cholesterol.
Obtained a jury verdict for DRIT, an investment partnership, in a patent licensing dispute against Glaxo Group over the lupus drug Benlysta®.
Ms. Goswami serves as Chair of the Patents Committee of the New York City Bar Association, as a Vice Chair of the Federal Circuit Bar Association’s PTAB and Trademark Trial and Appeal Board (TTAB) Committee, and has previously served on Law360’s Life Sciences Editorial Advisory Board. She is a member of the Diversity Committee of the PTAB Bar Association and a Director of the South Asian Bar Association of New York.
For her patent litigation work, Ms. Goswami has been repeatedly recognized by IAM Patent 1000 and The Legal 500 US, including as a “Next Generation Partner.” She was named a 2023 "Rising Star" by The New York Law Journal, and Benchmark Litigation has recognized her as a "Future Star" and named her to its “40 & Under List.” Ms. Goswami has also been named to Lawdragon’s “500 Leading Litigators in America” and “500 X – The Next Generation” lists. In 2022, she received LMG Life Sciences’ “US Rising Star – Intellectual Property” award and Euromoney Legal Media Group’s Rising Star Award for “Best in Patent,” and she was named to Patexia Insight’s list of Top IPR Attorneys of 2022.
Ms. Goswami was born in Washington, D.C. She received a B.S.E. in Chemical Engineering from Princeton University in 2009 and obtained certificates (minors) in Engineering Biology and Materials Science. At Princeton, she was awarded the inaugural leadership prize in Materials Science and Engineering. She received a J.D. magna cum laude from New York University School of Law in 2012, where she was a Florence Allen Scholar, a Senior Editor of the Journal of Intellectual Property & Entertainment Law and was elected to the Order of the Coif. At NYU, she was awarded the Walter J. Derenberg Prize in Copyright Law. She also received the Sidney B. Williams, Jr. scholarship from the Foundation for Advancement of Diversity in IP Law.
Ms. Goswami joined Cravath in 2012. She served as a law clerk to Hon. Timothy B. Dyk of the U.S. Court of Appeals for the Federal Circuit in 2013. She rejoined Cravath in 2014 and was elected a partner in 2019. Ms. Goswami serves on the Firm’s Diversity Committee and is a partner liaison to the South Asian Affinity Group/Middle Eastern Affinity Group.
Federal Circuit Bar Association, PTAB and TTAB Committee
New York City Bar Association, Patents Committee
PTAB Bar Association, Diversity Committee
South Asian Bar Association of New York
Law360
Benchmark Litigation
Euromoney Legal Media Group
Intellectual Asset Management
Lawdragon
The Legal 500 US
New York Law Journal
Deals & Cases
January 31, 2023
In January, 2023, Cravath client Abiomed Inc. (“Abiomed”) secured a victory before the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”).
Deals & Cases
September 02, 2022
On September 1, 2022, Chief Administrative Law Judge D. Michael Chappell of the Federal Trade Commission (“FTC”) ruled in favor of Cravath client Illumina, rejecting the FTC’s challenge to Illumina’s $8 billion acquisition of GRAIL, which closed in August 2021.
Accolades
October 11, 2023
On October 2, 2023, Cravath partner Sharonmoyee Goswami was featured as a 2023 “Rising Star” by the New York Law Journal. The accompanying profile published by NYLJ highlights Sharon’s representation of clients across all stages of litigation related to complex scientific issues, from pre‑complaint investigation through appeal, and her pro bono work involving issues including asylum, employment discrimination and hate crime litigation. Sharon also shared advice for young lawyers, encouraging them to know their “client’s business backwards and forwards” to become “a go‑to resource for the client as well as for the partners and senior associates on your team,” which can lead to greater leadership opportunities.
Accolades
August 10, 2023
On August 9, 2023, Cravath partner Sharonmoyee Goswami was named a 2023 “Rising Star” by the New York Law Journal. The award recognizes “the New York legal community’s emerging leaders.” Winners will be featured online and honored at an event in October.
Accolades
August 02, 2023
Cravath partners Michael P. Addis, Helam Gebremariam, Sharonmoyee Goswami, Lauren R. Kennedy, David H. Korn, Lauren M. Rosenberg, Brittany L. Sukiennik and Michael J. Zaken were named by Benchmark Litigation to its 2023 “40 & Under List.” The list honors the achievements of the nation’s most accomplished litigators of 40 years old and under who are “leading high‑profile cases and building significant reputations in their respective practices.” The list was compiled through a process involving peer and client review, along with examination of individual cases.
Activities & Publications
February 07, 2023
On January 31, 2023, Cravath partner Sharonmoyee Goswami participated in a program entitled “Patent Law Year in Review 2022,” which was hosted virtually by the Federal Circuit Bar Association, of which Sharon is vice chair of the PTAB and TTAB Committee. Sharon’s session discussed developments in patent law in 2022, including enablement and written description, patent venue, litigation procedures and key decisions issued by the Federal Circuit, and Patent Trial and Appeal Board (“PTAB”) proceedings.
Activities & Publications
December 06, 2022
On December 1, 2022, Cravath partner Sharonmoyee Goswami participated in a webcast entitled “PTAB Ten Years After: Where Are We Now and Where are We Going?” which was hosted by The Federal Circuit Bar Association’s PTAB and TTAB Committee, of which Sharon is vice chair. Sharon moderated the session, which examined the increasing usage of Inter Partes Reviews and Post‑Grant Reviews, recent actions of the U.S. Patent Trial and Appeal Board, and the prospect for post‑grant proceedings in the future.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.